ITRMF (Iterum Therapeutics) LT-Debt-to-Total-Asset: 1.03 (As of Sep. 2025)


What is Iterum Therapeutics LT-Debt-to-Total-Asset?

Iterum Therapeutics ITRMF +18.86% LT-Debt-to-Total-Asset is 1.03 as of Sep. 2025. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Iterum Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2025 was 1.03.

Iterum Therapeutics's long-term debt to total assets ratio increased from Sep. 2024 (0.55) to Sep. 2025 (1.03). It may suggest that Iterum Therapeutics is progressively becoming more dependent on debt to grow their business.

Iterum Therapeutics  (OTCPK:ITRMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Iterum Therapeutics LT-Debt-to-Total-Asset Related Terms

Iterum Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics LT-Debt-to-Total-Asset Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 1.09 0.27 0.43 0.72 0.70

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.70 0.97 0.95 1.03

Iterum Therapeutics LT-Debt-to-Total-Asset Calculation

Iterum Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=31.071/44.595
=

Iterum Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (Q: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2025 )/Total Assets (Q: Sep. 2025 )
=33.454/32.503
=1.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 1.03 mean?
Iterum Therapeutics (ITRMF) has a LT-Debt-to-Total-Asset of 1.03 as of Sep. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Iterum Therapeutics and its competitors.
Is Iterum Therapeutics' LT-Debt-to-Total-Asset too high?
Iterum Therapeutics' current LT-Debt-to-Total-Asset is 1.03.
How does Iterum Therapeutics' LT-Debt-to-Total-Asset compare to ENSC and PPCB?
Iterum Therapeutics' LT-Debt-to-Total-Asset of 1.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current LT-Debt-to-Total-Asset is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current LT-Debt-to-Total-Asset of 1.03. The current LT-Debt-to-Total-Asset is 1.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current LT-Debt-to-Total-Asset is 1.03 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.